Researchers have invented a cheap, portable, microchip-based test for diagnosing type-1 diabetes that could speed up diagnosis and enable studies of how the disease develops.
An inexpensive, portable, microchip-based test for diagnosing type-1 diabetes could improve patient care worldwide and help researchers better understand the disease, according to the device’s inventors at the Stanford University School of Medicine.
Described in a paper published online July 13 inNature Medicine, the test employs nanotechnology to detect type-1 diabetes outside hospital settings. The handheld microchips distinguish between the two main forms of diabetes mellitus, which are both characterized by high blood-sugar levels but have different causes and treatments. Until now, making the distinction has required a slow, expensive test available only in sophisticated health-care settings. The researchers are seeking Food and Drug Administration approval of the device.
“With the new test, not only do we anticipate being able to diagnose diabetes more efficiently and more broadly, we will also understand diabetes better — both the natural history and how new therapies impact the body,” said Brian Feldman, MD, PhD, assistant professor of pediatric endocrinology and the Bechtel Endowed Faculty Scholar in Pediatric Translational Medicine. Feldman, the senior author of the paper, is also a pediatric endocrinologist at Lucile Packard Children’s Hospital Stanford.
Better testing is needed because recent changes in who gets each form of the disease have made it risky to categorize patients based on their age, ethnicity or weight, as was common in the past, and also because of growing evidence that early, aggressive treatment of type-1 diabetes improves patients’ long-term prognoses.
Read more . . .
The Latest on: Diabetes
via Google News
The Latest on: Diabetes
- Philadelphia diabetes drug developer seeks partner to help advance lead product candidateon December 11, 2019 at 12:13 pm
The successor to one of Philadelphia’s oldest life sciences companies, started three decades ago to focus on diagnostics, is looking for a partner — or partners — to help bring its new drug candidate ...
- Weaponizing stem cells in the war on diabeteson December 11, 2019 at 6:54 am
There's no sugar coating it—diabetes is shaping up to become one of the greatest health challenges in modern times. According to the World Health Organization (WHO), one in eleven individuals suffers ...
- Recognizing 'diabetes burnout' early is key to heading it offon December 11, 2019 at 6:17 am
Dec. 11 --Living with diabetes -- especially if you need insulin to survive -- is a never-ending job that can be life-threatening if done wrong. That constant daily stress can lead to "diabetes ...
- 'It comes down to pure greed': Insulin prices double, causing many people with diabetes to turn to extremeson December 10, 2019 at 4:01 pm
COLUMBUS, Ohio – Mindi Patterson’s family pays nearly $1,000 each month for insulin. Her husband, Roc, 47, and her two sons, 19-year-old Pierce and 14-year-old Martin, all have Type 1 diabetes and ...
- Do Women With Diabetes Need More CVD Risk Reduction Than Men?on December 10, 2019 at 7:51 am
BUSAN, SOUTH KOREA — Whether cardiovascular disease risk reduction efforts should be more aggressive in women than men with the diabetes depends on how you interpret the data. Two experts came to ...
- Duration of diabetes history tied to higher short-term mortality riskon December 10, 2019 at 7:24 am
In older adults, long-standing diabetes has a substantial and independent effect on short-term mortality, according to a study published online Nov. 27 in Diabetes Care. Olive Tang, from the Johns ...
- FDA Investigating Diabetes Drug Metformin for Traces of Cancer-Linked Chemical NDMAon December 10, 2019 at 5:10 am
The U.S. Food and Drug Administration (FDA) is investigating whether a drug used to treat diabetes is contaminated with traces of a chemical thought to increase the risk of developing cancer. The ...
- Sanofi, Maker of World’s Top-Selling Insulin, to Exit Diabetes Researchon December 9, 2019 at 6:43 pm
Sanofi said it would stop investing in diabetes research after years of frustrated attempts to bring a fresh blockbuster to the market.
- Diabetes patients turning to black market as costs skyrocketon December 9, 2019 at 2:48 pm
Dec. 9 --Skyrocketing prices and insurance limits are driving many people with diabetes to seek medications and supplies from an underground supply chain, a new study found. "The cost of insulin, ...
- Sanofi ends research in diabetes, narrows units to spur profitson December 9, 2019 at 1:27 pm
Sanofi ( SASY.PA) on Monday said it would end its research efforts in diabetes and cardiovascular diseases as part of a reorganization plan that will narrow the number of its global business units in ...
via Bing News
